Clinical Trials Logo

Clinical Trial Summary

Uterine fibroids are are the most common gynecological tumor. Among the pharmacological treatment options, ulipristal acetate (UPA) has proven to be effective in control of bleeding and reduction of size of fibroids. Due to the appearance of some cases of subacute severe hepatic insufficiency in patients undergoing UPA treatment and the possible idiosyncratic effect of the drug, the European Medicine Agency (EMA) recommended performing liver function tests before, during and after each UPA treatment course as a minimization risk strategy to prevent drug induced liver injury (DILI). The aim of the present study is to evaluate whether changes in transaminase levels or other DILI markers occur in patients receiving UPA in our center.


Clinical Trial Description

INTRODUCTION Fibroids are benign monoclonal tumors originated from genetically predisposed uterine smooth muscular cells in a proper hormonal environment. Fibroid growth is dependent on the ovarian steroids estrogen and progesterone. In vivo models have shown that progesterone and the presence of its receptor are the main key points for fibroid growth, being PR stimulation the primary action of estrogens. Multiple treatment options are currently available, including surgery (hysterectomy or myomectomy), uterine artery embolization, cryomyolysis, radiofrequency myolysis, high-intensity focused ultrasound, and pharmacological treatment. Proper counseling about all therapeutic approaches should be discussed with the patient, explaining pros and cons of every treatment and taking into consideration several clinical factors such as number, location and fibroid size, age and desire for future pregnancies. Final decision of the best treatment should be taken according to the patient's desire. Uterine fibroids still represent the most frequent indication for hysterectomy, which associates a low but significant risk of vascular, intestinal and urinary complications. Non-surgical treatments represent a good option for those young patients in order to avoid surgical scars on uterine surface and the risk of hysterectomy. Due to the Es and Prog dependent status, fibroid-related symptoms often cease once menopause status is achieved, so selected perimenopausal patients could also benefit from those therapies and avoid a surgery. Among the pharmacological treatment options, gonadotropin-releasing hormone agonists (GnRHa) are effective in reducing bleeding and uterine volume, but with considerable side-effects due to the estrogen-suppression status. Ulipristal acetate (UPA) have been shown to be effective in bleeding control, induction of amenorrhea and fibroid reduction when compared to GnRHa, with fewer side effects as it maintains estradiol at mid-follicular phase levels. Pre-surgical UPA treatment allows recovery of Hb levels and reduction in fibroid size, allowing better minimally invasive surgery procedures. On selected patients, long-term intermittent treatment with UPA offers an alternative to surgery allowing patients to reach menopause status without surgery. In February 2018, the European Medicines Agency (EMA) announced temporary restrictive measures to UPA treatment as 8 cases of severe liver injury were potentially linked to UPA administration. After the Pharmacovigilance Risk Assessment Committee (PRAC) evaluation concluded, the association between UPA and drug induced liver injury (DILI) was neither confirmed nor excluded. As a conclusion, the EMA stated that the benefits of UPA for the treatment of symptomatic uterine fibroids clearly outweigh the risks, but risk-minimization measures were needed in order to avoid the rare but serious possible liver injury. In this work, the investigators evaluated evaluate whether changes in transaminase levels or other DILI markers occur in patients receiving UPA in the study center. MATERIAL AND METHODS Retrospective observational study to assess the variations of liver blood test parameters during UPA treatment for symptomatic uterine fibroids. The study is approved by the ethics committee of the study site and will be conducted in accordance with the principles of the International Conference on Harmonization-Good Clinical Practice (ICH-GCP) guidelines Investigators will include all women who had completed a full 12-week treatment course of UPA for symptomatic uterine fibroids since September 2018. All patients will provide written informed consent. As stated by EMA recommendations, all patients will perform a blood test including liver parameters (AST, ALT, AF, GGT, bilirubin) before initiating the treatment, monthly during the 12-week treatment course, and an additional test 2-4 weeks after ending treatment. All data will be collected in an anonymized database with restricted access to investigators ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04004884
Study type Observational
Source Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Contact
Status Terminated
Phase
Start date May 23, 2019
Completion date December 31, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05098197 - Study on TIL for the Treatment of Advanced Hepatobiliary-Pancreatic Cancers Early Phase 1
Recruiting NCT05098184 - Study on TIL for the Treatment of Advanced Melanoma Early Phase 1
Recruiting NCT05098171 - Study on Signal Switch Receptor Modified TIL for the Treatment of Advanced Gynecologic Tumors Early Phase 1
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Recruiting NCT06057350 - Surgery Versus Endoscopic Resection for Incompletely Removed Early Colon CAnceR N/A
Recruiting NCT05084625 - PACED-digitized Support During Adjuvant Endocrine Therapy N/A
Recruiting NCT05092074 - Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
Active, not recruiting NCT04986670 - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer N/A
Recruiting NCT05142475 - Study on TIL for the Treatment of Advanced Breast Cancer Early Phase 1
Completed NCT04913350 - Contralateral Effects of Russian Current on Adolescent Athlete N/A
Recruiting NCT04768582 - Platelet Reactivity After an Eastern Asian Loading Dose of Prasugrel in Taiwanese ACS Patients N/A
Recruiting NCT05767866 - Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR Phase 1/Phase 2
Recruiting NCT06340516 - NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity N/A
Recruiting NCT06315582 - Surgical Approach to Uterine Septum N/A
Recruiting NCT05468307 - Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors Early Phase 1
Not yet recruiting NCT05085808 - RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ) Phase 4
Recruiting NCT04923100 - Therapeutic Effect of New Biologics in Crohn's Disease
Recruiting NCT05446051 - Development and Testing of a TTDSS for Cancer Patients N/A
Recruiting NCT05030701 - Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not
Recruiting NCT05492487 - A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore Phase 2